VMD-928

· VM Oncology, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VMD-928, covering 2025-12-11 to 2025-12-11. Get the full timeline:

Most recent: Clinical Trial Update: VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma [Phase 1, Phase 2]

See pricing